Except for ICU patients, ceftolozane-tazobactam is a treatment option for multi-drug resistant P. aeruginosa.

Gram-negative bacilli and especially P. aeruginosa are responsible for increasingly multi-drug resistance challenging problems. The association between a new cephalosporin and a well-established beta-lactamase inhibitor could be interesting in these cases. Although in France, labeled indications for ceftolozane-tazobactam (C/T) are limited to infections due to P. aeruginosa resistant to other b...